Current Biology
Volume 15, Issue 14, 26 July 2005, Pages 1257-1265
Journal home page for Current Biology

Article
Positive Selection on a High-Sensitivity Allele of the Human Bitter-Taste Receptor TAS2R16

https://doi.org/10.1016/j.cub.2005.06.042Get rights and content
Under an Elsevier user license
open archive

Summary

Background: During periods of human expansion into new environments, recognition of bitter natural toxins through taste may have conferred an important selective advantage. The G protein-coupled receptor encoded by TAS2R16 mediates response to salicin, amygdalin, and many bitter β-glucopyranosides. β-glucopyranosides are ubiquitous in nature, with many having a highly toxic cyanogenic activity.

Results: We examined evidence for natural selection on the human receptor TAS2R16 by sequencing the entire coding region, as well as part of the 5′ and 3′ UTRs, in 997 individuals from 60 human populations. We detected signatures of positive selection, indicated by an excess of evolutionarily derived alleles at the nonsynonymous site K172N and two linked sites and significant values of Fay and Wu’s H statistics in 19 populations. The estimated age range for the common ancestor of the derived N172 variant is 78,700–791,000 years, placing it in the Middle Pleistocene and before the expansion of early humans out of Africa. Using calcium imaging in cells expressing different receptor variants, we showed that N172 is associated with an increased sensitivity to salicin, arbutin, and five different cyanogenic glycosides.

Conclusion: We have detected a clear signal of positive selection at the bitter-taste receptor gene TAS2R16. We speculate that the increased sensitivity that is shown toward harmful cyanogenic glycosides and conferred by the N172 allele may have driven the signal of selection at an early stage of human evolution.

Cited by (0)

5

Present address: Public Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG Scotland.

6

Present address: Center for Population Genomics and Pharmacogenetics, Duke Institute for Genomic Sciences and Policy, Duke University, DUMC Box 3471, 4006 GSRB II, 103 Research Drive, Durham, North Carolina.